PPARG and esophageal squamous cell carcinoma: PPAR-γ expression was studied in patients with esophageal squamous cell carcinoma (ESCC), on which the antiproliferative effect and mechanism of action of the PPAR-γ agonist, ephatutazone, were investigated.